Introduction
Adipose tissues have important functions in the regulation of energy balance.
Adipocytes store excess energy supply as triglyceride droplets, resulting in the development of obesity. During fasting and exercise, triglycerides stored in the cells are hydrolyzed producing glycerol and free fatty acids, which are important oxidative fuels for other tissues such as liver, skeletal muscle, kidney, and the myocardium.
Different hormones govern the use of energy in the triglyceride depots (1, 2) .
Rat adipocytes contain three β-adrenergic receptor (β-AR) subtypes: β1, β2, and β3.
The three β-ARs are coupled with Gs protein and transmit an activation signal to adenylylcyclase, leading to an increase in cAMP. The resulting activation of protein kinase A (PKA) mediates activation of hormone-sensitive lipase (HSL), which hydrolyzes triglycerides stored in the cells (1, 2) . The fact that the protein level of β2-AR is extremely low (3) and that lipolysis stimulated by norepinephrine and isoproterenol is not significantly affected by a β2-AR antagonist ICI 118551 (4) indicate a very minor role of the β2-AR signaling for lipolysis in rat adipocytes. β3-AR may represent the physiological receptor for high norepinephrine concentrations (100 nM), attained by sympathetic activity near adipose tissues in conditions such as fasting and cold exposure (5, 6) . In rat adipocytes, norepinephrine at concentrations usually found in the circulation (1−25 nM) stimulates mainly the high-affinity β1-AR and thereby induces lipolysis (5) . In humans, circulating catecholamine stimulates the β1-and β2-ARs, which are critical determinants for the rate of lipolysis induced by submaximal exercise in subcutaneous adipose tissue (7) and lipolysis in response to insulin-induced hypoglycemia in skeletal muscle (8) .
The rate of lipolysis is regulated not only by lipolytic hormones but also by antilipolytic hormones. Insulin is the most potent antilipolytic hormone in adipose tissues. It inhibits the activity of HSL by decreasing the cAMP level through phosphorylation and activation of phosphodiesterase 3B (PDE3B) (1). PDE3B stimulation by insulin requires the activities of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB) (1, 9, 10) . Lipolysis is also inhibited by the activities of 6 α2-AR and adenosine receptor that couple to Gi protein and inhibit adenylylcyclase, and by other activities of different effector molecules (1, 2) .
Using rat adipocytes, we have shown that phorbol 12-myristate 13-acetate (PMA) attenuates lipolysis induced by submaximally stimulating concentrations of isoproterenol and norepinephrine (4) . The decrease in lipolysis by PMA may be due to specific inhibition of the β1-AR system by the activity of protein kinase C (PKC). In this study, we attempted to characterize the signaling pathway of PKC-dependent antilipolysis in rat adipocytes. It was found that stimulation of insulin receptor substitutes for the action of PMA. The effect of insulin on lipolysis was blocked by PKC inhibitors and wortmannin.
Materials and methods

Materials
The β-AR agonists, isoproterenol and dobutamine, and the β1-AR antagonist, CGP 20712A, were purchased from Sigma (St. Louis, USA). Angiotensin II, phenylephrine, and methoxamine were from Wako Pure Chemical Industries (Osaka, Japan). The PKC inhibitors, Gö 6976 and LY 333531, were from Calbiochem (Darmstadt, Germany) and Alexis (San Diego, USA), respectively. PMA, wortmannin, and protease inhibitor cocktail were from Sigma. The rabbit anti-peptide antibodies recognizing PKCα, βI, and βII were purchased from Santa Cruz Biotechnologies (Santa Cruz, USA) and the rabbit anti-peptide antibodies to PKCδ, ε, and ζ were from Sigma.
Animals and adipocyte preparation
Male rats of the Charles River CD strain weighing 200−240 g (7 weeks old) were used. Animals were fed a standard commercial diet ad libitum and allowed free access to water. The light cycle was 08:00−20:00. Isolated adipocytes were prepared from the epididymal fat pads by the method previously described (4) 
Lipolysis and glycerol measurement
The packed adipocytes were diluted 10-fold with buffer A, and incubated at 37ºC for 20 min in the presence of pharmacological agents. The concentration of glycerol in the incubation mixture was measured to determine the rate of lipolysis. Lipolysis, as assessed by glycerol release, linearly increased for at least 40 min (11).
Western blot analysis
Adipocytes were washed three times with a buffered solution containing 10 mM Tris, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, and 0.5% protease inhibitor cocktail.
Then, cells were processed for separation of the cytosol and membrane fractions as 9 described previously (4).
The membrane fraction from adipocytes was mixed with the sample-loading buffer, and subjected to sodium dodecylsulphate (SDS)-polyacrylamide gel electrophoresis followed by electrotransfer of protein onto a polyvinylidene difluoride membrane (4).
After incubation of the membrane with the primary and secondary antibodies, immunoreactive bands were detected by ECL Plus (Amersham, UK). Samples that were compared from each experiment were analyzed on the same immunoblot, and relative changes in the density of the bands were determined by scanning densitometry.
Statistics
Each experiment was performed in duplicates and repeated three times or more.
Results were mean values ± SEM. In some cases, data were expressed as the percentage of the activity in control cells (taken as 100%). If necessary, data were examined by Student's t test to evaluate the statistical significance.
Results
Effects of insulin, angiotensin II, and α1-AR agonist on the lipolysis-attenuating effect of PMA
Rat adipocytes possess a PKC-dependent signaling pathway for antilipolysis (4) .
To explore the mechanism of PKC signaling, adipocytes were treated with insulin, angiotensin II, and α1-AR agonist, which are known to activate the PKC pathway (2, Thus, insulin causes a reversible and an irreversible inhibition of lipolysis.
Next, adipocytes were treated with angiotensin II and α1-AR agonists, phenylephrine and methoxamine, and lipolysis was induced in the presence and absence of PMA before washing out the agents. PMA was found to significantly attenuate lipolysis (Fig. 2) . Methoxamine decreased lipolysis, but PMA further reduced it. The lipolysis-attenuating effect of PMA was detected in adipocytes that had been treated with angiotensin II, phenylephrine, and methoxamine for 30 min, and the agents were washed out (results not shown).
Effects of PKC inhibitor and β1-AR antagonist on lipolysis
In the following experiments, lipolysis was stimulated by 0.8 µM dobutamine, as the effect of insulin was apparent (Fig. 1) . The results shown in Fig. 1 indicate that insulin may substitute for PMA and attenuate lipolysis. To assess the significance of PKC activity, the effects of the PKCα-and β-specific inhibitor Gö 6976 (18) and the PKCβ-specific inhibitor LY 333531 (19) were determined in the insulin-treated adipocytes. In the previous study (4), Gö 6976 was found to increase lipolysis in the untreated adipocytes in the presence of PMA in a dose-dependent manner, and the lipolysis-attenuating effect of PMA disappeared in the presence of 0.3−3 µM Gö 6976.
Similarly, the effect of PMA was suppressed by LY 333531 at concentrations of 0.5 µM or more (results not shown). Fig. 3 shows that lipolysis in the insulin-treated cells is increased by 3 µM Gö 6976 much more than that in the control cells, resulting in a comparable level to the control. LY 333531 at concentrations of 0.5 µM or more increased lipolysis in the insulin-treated cells to the control levels (Fig. 3) .
The β1-AR antagonist CGP 20712A greatly decreased lipolysis induced by dobutamine in both control and insulin-treated cells, and abolished the difference in the rate of lipolysis between two cell preparations (Fig. 4) . The lipolysis-attenuating effect of PMA in the control cells as well as the increase of lipolysis by Gö 6976 in the insulin-treated cells were not found in the presence of CGP 20712A.
Effects of wortmannin on the lipolysis-attenuating effect of PMA
Biological actions of insulin in the adipose tissues are mediated by the cell-surface receptor with intrinsic tyrosine kinase activity. One of the immediate targets of the 13 insulin receptor is the insulin-receptor substrates (IRSs), and phosphorylation of IRSs on specific tyrosines creates binding sites for src homology-2 (SH2) domain-containing proteins, including PI3K (10, 20) . Recruitment and activation of PI3K initiates a series of events leading to biological actions of insulin (9, 10, 20) . Wortmannin, a PI3K inhibitor (21), inhibits many of insulin's effects on glucose and lipid metabolism (9, 10, 20) . In the present study, wortmannin increased lipolysis in a dose-dependent manner in the insulin-treated cells as well as lipolysis, to a lesser extent, in the control cells ( 
Western blot analysis of PKC isoforms
In the previous report (4), we have shown that rat adipocytes express PKCα, βI, βII, δ, ε, and ζ. PKCα, βI, and βII showed translocation from cytosol to membrane in response to acute treatment with PMA. In this study, the amounts of membrane-bound PKC isoforms were determined before and after the treatment of adipocytes with 20 nM insulin for 30 min by Western blot analysis. As shown in Fig.   6 , insulin caused slight increases of the membrane-bound PKCα, βI, and δ. An increase of 19% was found in the membrane-bound PKCβII; however, this was not significant.
The data shown in Fig. 5 indicate that the active form of PKC responsible for antilipolysis in this study is rapidly decreased by wortmannin. To examine this, adipocytes were treated with insulin followed by incubation with wortmannin for 10 and 30 min, and the amounts of membrane-bound PKC isoforms were determined (Fig.   6 ). PKCβI and βII decreased after 10 min of treatment with wortmannin (Fig. 6) . A decrease of PKCδ was found after 30 min of treatment with wortmannin. No marked 15 change by wortmannin was found in the membrane-bound PKCα, ε, and ζ.
Discussion
Recently, we have shown that PKC is a regulator of lipolysis induced by submaximally stimulating concentrations of β1-AR agonists (4). The present study shows that exposure of rat adipocytes to insulin followed by washing out insulin decreases lipolysis induced by low concentrations of the β1-AR agonist dobutamine. Conventional and novel PKCs after activation by diacylglycerol bind to membrane through interaction with receptors of activated C-kinase (RACKs) and other PKC-interacting proteins (C-KIPs) for biological functions (23, 24) . In adipocytes, insulin promotes translocation of PKCα and β to membrane (14, 25, 26) . However, no consistent changes of intracellular distribution of PKCδ, ε and ζ by insulin have been reported (14, 25, 26) . In this study, we found small increases in the membrane-bound PKCα, βI, and δ after treatment of adipocytes with 20 nM insulin for 30 min. It is known that the insulin-induced translocation of the PKC isoforms is very rapid and transient, and the membrane-bound PKC isoforms are maximal at 2−10 min of insulin treatment and then decrease in a time-dependent manner (14, 25, 26) . Because of prolonged treatment in the present study, no marked increase of the membrane-bound PKC by insulin could be detected.
Even with such small increases, lipolysis in the insulin-treated cells apparently responded to the PKC inhibitors, but not to PMA.
Wortmannin suppressed the effect of insulin and recovered the lipolysis-attenuating effect of PMA. These data suggest that the PKC isoform responsible for antilipolysis was activated in the insulin-treated cells.
There are reports suggesting that activation and translocation of PKC by insulin are insensitive to wortmannin (12, 27) . However, other studies have shown that wortmannin inhibits both insulin-mediated translocation of PKC (14, 28) and glucose uptake (14) . In this study, wortmannin inhibited the PKC-dependent antilipolysis by insulin and decreased the levels of PKC isoforms in the membrane fraction. Insulin may acts through PI3K to activate phospholipase C and phospholipase D, leading to production of diacylglycerol (13, 14, 22) . Binding of diacylglycerol to PKC results in a high-affinity interaction of PKC with the specific membrane sites (29) , which is essential for PKC to accomplish biological functions (23, 24) . Wortmannin has been shown to inhibit diacylglycerol production (14, 22) . Wortmannin does not directly inhibit PKC or affect translocation of PKC isoforms or glucose uptake by PMA (14, 28) .
Accordingly, wortmannin did not inhibit the effect of PMA on lipolysis in the control and insulin-treated adipocytes. Translocation of PKCα, βI, and βII to membrane by
PMA was not inhibited by wortmannin (results not shown).
It is well known that, upon interaction with the specific membrane sites, PKC is irreversibly activated and plays a role in signaling after Ca 2+ and diacylglycerol have returned to basal levels (23) . This sustained activation of the enzyme may account for the PKC-dependent antilipolysis found after washing out insulin. Alternatively, insulin tightly bound to the insulin receptor, which is not immediately removed by washing with an insulin-free buffer (30, 31) , may sustain signaling for the activation of PKC. Adipocytes that are treated with insulin followed by washing out insulin still
show the acute effects of insulin (30, 31) . Insulin, present in the incubation mixture, provokes a prolonged increase of phosphatidylinositol 3,4,5-triphosphate (PIP3), a PI3K
by product, in adipocytes that persists at least for 1 h with no marked decrease (32, 33) , For full activation, PKB is phosphorylated at two sites by 3-phosphoinositide-dependent kinase-1 (PDK1) and PDK2 (37) . Activation and translocation of PDK1 and PDK2 depend on PIP3. Recently, PKCβII was shown to act as a PDK2 activity in some cases for activation of the catalytic domain of PKB (38).
Thus, it is possible that PKCβII stimulated by insulin activates PKB, which then causes phosphorylation and activation of PDE3B. To assess this possibility, the effect of a PDE3B inhibitor cilostamide (10) on the lipolysis-attenuating effect of PMA was determined. In the untreated adipocytes, the effect of PMA was clearly detected in the presence of cilostamide (4) . Cilostamide at a concentration of 1 µM increased lipolysis in the insulin-treated adipocytes to a level higher than the control, although the mechanism is unclear. Moreover, addition of PMA to the mixture containing cilostamide decreased lipolysis with a 29.2 ± 3.6 % inhibition (mean ± SEM, p < 0.01, n = 6). The results suggest that rat adipocytes possess a PKC-dependent antilipolytic pathway, which is independent of the PDE3B activity. The control-, insulin-, and insulin/wortmannin-treated cells were washed and subjected to preparation of the membrane fractions. Western blot analysis was performed by using the antibobies specific to PKCα, βI, βII, δ, ε, and ζ as described in Materials and 
